(Q34656379)

3 August 2017

Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review (English)

1 reference

3 August 2017

0 references

0 references

1 reference

1 reference

Ellen Rafferty

1

1 reference

3 August 2017

Philippe Duclos

series ordinal

2

1 reference

3 August 2017

Sergio Yactayo

series ordinal

3

1 reference

3 August 2017

Melanie Schuster

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

27 September 2013

1 reference

3 August 2017

1 reference

3 August 2017

31

1 reference

3 August 2017

49

1 reference

3 August 2017

5798-5805

1 reference

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Yellow fever 17D vaccine safety and immunogenicity in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Rare case of fatal yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Yellow fever-associated viscerotropic disease in Barcelona, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Viscerotropic disease following yellow fever vaccination in Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

A Case of Yellow Fever Vaccine-Associated Viscerotropic Disease in Ecuador

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Genetic divergence and dispersal of yellow fever virus, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Risk of fatal adverse events associated with 17DD yellow fever vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Yellow Fever Vaccine Post-marketing Surveillance in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

Review of the risks and benefits of yellow fever vaccination including some new analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.030

10.1016/J.VACCINE.2013.09.030

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference